Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 3. Rapid correction of low vitamin D status in nursing home residents 4. 2008 Exclusive Survey—Earnings: Good news for primary care income 5. Medicare pay-for-reporting effort draws fire from frustrated doctors
Your Article Summary
The combined low-dose dexamethasone suppression corticotropin releasing-hormone test as a tool to rule out Cushing's syndrome
European Journal of Endocrinology, 11/04/08
Reimondo G et al. - The authors suggest that LDDST-CRH test may still find a place as a rule-out procedure in patients who present with indeterminate results after screening and may be unavailable to repeat testing during follow-up.
| Previous Article | Next Article |
Today in Diagnostics...keeping you current
Receive free subspecialty "5-minute updates" via email
Diabetes Experts Recommend A1c Testing for Diabetes Diagnosis
American Family Physician, 06/25/09
Continuous Glucose Sensing: Future Technology Developments
Diabetes Technology & Therapeutics, 06/05/09
Continuous Glucose Monitoring Health Outcomes
Diabetes Technology & Therapeutics, 06/04/09
Today in Neuroendocrinology...keeping you current
Receive free subspecialty "5-minute updates" via email
Gemcitabine and oxaliplatin combination chemotherapy for metastatic well-differentiated neuroendocrine carcinomas
Cancer, 06/01/09
Overweight in midlife and risk of dementia: A 40-year follow-up study
International Journal of Obesity, 06/19/09
Practical approach to childhood craniopharyngioma: A role of an endocrinologist and a general paediatrician
Child's Nervous System, 06/23/09
Today in Pharmacology/kinetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Denosumab update
Current Opinion in Rheumatology, 06/11/09
Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study)
The American Journal of Cardiology, 06/22/09
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): A multicentre, randomised, open-label trial
The Lancet - Early Online Publication, 06/09/09
Sponsor
Article Search
Sponsor


See Latest Articles


